UCB, Sanofi to co-promote antihistamine Xyza in United States

By Lisa Kerner

Charlotte, N.C., Sept. 25 - UCB and Sanofi-aventis entered into an agreement to co-promote the once-daily antihistamine medicine, Xyza (levocetirizine dihydrochloride) in the United States.

The drug, originally launched in Europe in 2001, is currently marketed in 49 countries.

UCB, a Brussels, Belgium biopharmaceutical company, began the Food and Drug Administration regulatory approval process in July to market Xyzal for seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria.

Under the terms of the agreement, Sanofi-aventis will book sales of the drug. The Paris pharmaceutical company will also pay an upfront payment, as well as milestone payments, to UCB.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.